GlassScriptPhysician profile
Amanda B Lee
NPI 1376864264
$6,756.12
in general payments reported to CMS, 2019-2025
45 companies · $1,588 in 2025
The $1,588 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,186 · 2022: $1,010 · 2023: $1,142 · 2024: $1,830 · 2025: $1,588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,541 · Education: $19.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,540.50 |
| Education | $19.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,516.24 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $499.42 | 2021-2025 | Entyvio, Gattex |
| Lilly USA, LLC | $360.75 | 2022-2025 | Omvoh, Mounjaro, Jardiance |
| Janssen Biotech, INC. | $327.63 | 2021-2025 | Simponi Aria, Simponi, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $281.97 | 2021-2025 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $166.64 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $164.61 | 2023-2025 | |
| Ardelyx, INC. | $156.80 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $141.30 | 2022-2025 | |
| Qol Medical, LLC | $132.30 | 2022-2025 | Sucraid, Sucraid |
| Novo Nordisk INC | $129.90 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Celgene Corporation | $128.64 | 2021-2024 | Zeposia |
| Bayer Healthcare Pharmaceuticals INC. | $120.47 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $111.55 | 2021-2022 | |
| Axonics, INC. | $109.85 | 2023 | Axonics |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $105.70 | 2025 | |
| Glaxosmithkline, LLC. | $102.16 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Regeneron Healthcare Solutions, INC. | $88.21 | 2022-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $87.07 | 2021-2024 | Dificid, Recarbrio, Zerbaxa |
| Redhill Biopharma INC. | $82.95 | 2021-2022 | |
| Exact Sciences Corporation | $80.45 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $75.83 | 2023-2025 | Freestyle Libre 3, Merlin@Home |
| Nestle Healthcare Nutrition INC. | $73.88 | 2021 | |
| Phathom Pharmaceuticals, INC. | $73.45 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $68.80 | 2024-2025 | Vowst |
| Ironwood Pharmaceuticals, INC | $68.09 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.83 | 2021 | |
| Boston Scientific Corporation | $45.61 | 2024-2025 | Watchman Flx, Wavewriter Alpha Prime 16 |
| Idorsia Pharmaceuticals US INC | $37.44 | 2023 | Quviviq |
| Ipsen Biopharmaceuticals, INC | $32.83 | 2025 | Iqirvo |
| Astellas Pharma US INC | $32.01 | 2024 | Veozah |
| Alnylam Pharmaceuticals INC. | $30.71 | 2025 | Givlaari |
| Braintree Laboratories, INC. | $30.34 | 2021-2024 | Sutab, Suflave |
| Eisai INC. | $28.29 | 2021 | |
| Amgen INC. | $27.46 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $27.30 | 2021-2024 | Airsupra |
| Celltrion USA INC. | $20.43 | 2025 | Vegzelma |
| Daiichi Sankyo INC. | $19.24 | 2022 | |
| Ucb, INC. | $18.56 | 2021 | |
| Teleflex LLC | $17.47 | 2024 | Solesta |
| Intercept Pharmaceuticals, INC. | $16.68 | 2021 | |
| Evoke Pharma, INC. | $16.66 | 2022 | |
| Lucid Diagnostics INC. | $15.65 | 2025 | |
| Sandoz INC. | $15.08 | 2023 | Hyrimoz |
| Shield Therapeutics INC | $14.87 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.